Study 18 of 247 for search of: Raltegravir OR Isentress[TREATMENT] AND HIV [CONDITION]
Previous Study Return to Search Results Next Study

Full Text View
Tabular View
No Study Results Posted
Related Studies
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
This study is currently recruiting participants.
Verified February 2012 by Yale University
Study NCT00814879   Information provided by Yale University

First Received on December 18, 2008.   Last Updated on February 28, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acquired Immune Deficiency Syndrome
AIDS
Human Immunodeficiency Virus
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
More general conditions related to this trial
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Raltegravir
Atazanavir
Standard treatment regimen
Additional drug interventions recognized in this trial
Anti-Infective Agents
HIV Protease Inhibitors
Reverse Transcriptase Inhibitors
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Yale University
Bristol-Myers Squibb
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services